2 not yet recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow EG-007: new trials by email Literature Review of EG-007 trials Research Report on EG-007
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer EG-007, Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection, Lenvatinib Capsules - Advanced Endometrial Cancer | Phase 3 | Not yet recruiting | Evergreen Therapeutics, Inc. | 450 | 2026-12-01 | 2025-12-08 |
| Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem EG-007, Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection, Lenvatinib Capsules - Advanced Endometrial Cancer | Phase 2 | Not yet recruiting | Evergreen Therapeutics, Inc. | 28 | 2026-08-01 | 2025-12-08 |